NASA Faces Major Workforce Reduction as 20% of Employees Prepare to Leave 
FDA Pilot Program Eases Rules for Nicotine Pouch Makers 
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment 
Nintendo Switch 2 Production Cut as Holiday Sales Miss Targets 
U.S. Officials Express Optimism Over New CDC Director Selection Amid Vaccine Policy Turmoil 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Goldman Sachs Raises ECB Rate Hike Forecast Amid Persistent Energy-Driven Inflation 
U.S. Stock Futures Steady as Iran Reviews U.S. Ceasefire Proposal 
FDA Warns Novo Nordisk Over Misleading Ozempic Ad Claims 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Oil Prices Slip as Middle East Tensions Ease, Heading for Weekly Loss 
Google's TurboQuant Algorithm Sends Memory Chip Stocks Tumbling 
Oil Prices Climb as Iran Reviews U.S. Peace Proposal Amid Middle East Tensions 
9 Tips for Avoiding Tax Season Cyber Scams 
China Opens Door to Stronger U.S. Trade Ties Amid Rising Tensions 
Researchers from the Korea Advanced Institute of Science and Technology (KAIST) have developed a wearable green organic light-emitting diode (OLED) with a 470-nanometer (nm) wavelength that can cure jaundice in infants.
The OLED provides sufficient power for jaundice treatment even at low voltage, durability for over 100 hours of operation, a low operating temperature of less than 35 Celsius degrees, and flexibility that can endure over 1,000 bends at a 2 mm radius of curvature.
The bilirubin level of the infants’ serum reaches 12 milligrams per decilitre (mg/dL) within three hours of being exposed to the OLED, indicating the completed treatment of jaundice.
Unlike existing light-emitting diode (LED)-based jaundice treatment devices currently used at hospitals, the OLED showed uniform and effective treatment functions.
